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Abbreviations 
ART: Arterial revascularization trial 
ATT: average treatment effect on the treated 
BITA: Bilateral internal thoracic arteries 
CABG: coronary artery bypass grafting 
COPD: chronic obstructive pulmonary disease 
IPTW: inverse probability of treatment weighting 
LVEF: left ventricular ejection fraction 
MAG: multiple arterial graft 
MI: myocardial infarction 
PCI: percutaneous coronary intervention 
PVD: peripheral vascular disease 
PS: propensity score 
RA: radial artery 
RCA: right coronary artery 
SAG: single arterial graft 
SITA: Single internal thoracic artery 
SVG: saphenous vein graft 
SMD: standardized mean difference  
TAG: total arterial graft  
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Abstract 1 
Background: The Arterial Revascularization Trial (ART) was designed to compare 10 years survival in 2 
bilateral (BITA) vs. single internal thoracic artery (SITA) grafts. The intention to treat analysis has 3 
showed comparable outcomes between the two groups but an explanatory analysis suggested that 4 
those receiving 2 or more arterial grafts had better survival. Whether the exclusive use of arterial 5 
grafts provide further benefit is unclear.  6 
Methods: We performed an exploratory analysis of the ART based on conduits actually received (as 7 
treated principle). Among 3102 patients enrolled in ART, only those receiving at least 3 grafts were 8 
included. Patients receiving single arterial graft (SAG) plus saphenous vein graft (SVG) were included 9 
in the SAG group; patients receiving 2 or more arterial grafts with additional SVG were included in 10 
the multiple arterial graft (MAG) group; patients receiving arterial grafts only were included in the 11 
total arterial graft (TAG) group. Inverse probability of treatment weighting (IPTW) was used for 12 
comparison.   13 
Results: The final population consisted of 1084, 1010 and 390 patients in the SAG, MAG and TAG 14 
group respectively. IPTW analysis showed that when compared to the SAG group, there was a 15 
significant trend toward a reduction of 10-year mortality in the MAG and TAG group (test for trend 16 
P=0.02) and TAG group was associated with the lowest risk of late mortality (HR 0.68; 95% CI 0.48-17 
0.96;P=0.03). TAG was also associated with a significant risk reduction of the composite of 18 
death/MI/stroke and repeat revascularization (HR 0.71; 95%CI 0.53-0.94; P=0.02).  19 
Conclusions: When compared to SAG, both MAG and TAG represent valuable strategies to improve 20 
clinical outcomes following CABG but TAG can potentially provide further benefit.  21 
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Introduction 22 
Graft failure after coronary artery bypass grafting (CABG) causes recurrent angina, need for repeat 23 
intervention and poorer survival [1]. Arterial grafts (AG) including bilateral internal thoracic artery 24 
(BITA) grafts and/or the radial artery (RA) have been consistently shown to provide superior 25 
angiographic patency rates when compared to saphenous vein grafts (SVG) [2-3] and the exclusive 26 
use of arterial grafts (total arterial grafting, TAG) has also been advocated as the best 27 
revascularization strategy [4-9]. However, TAG is still largely underutilised to supplement a single 28 
arterial graft (SAG) and multiple arterial graft (MAG) strategies.  29 
The Arterial Revascularization Trial (ART) was designed to compare 10 years survival in bilateral 30 
(BITA) vs. single internal thoracic artery (SITA) grafts. The intention to treat analysis has shown 31 
comparable outcomes between the two groups [10]. However, SVG was used in 60% of BITA grafts 32 
and this may have partially contributed to the equipoise observed in the intention to treat analysis.  33 
Hence, we aimed to investigate the potential advantage of TAG versus MAG with additional SVG 34 
over SAG strategy by performing an exploratory analysis of the ART based on conduits actually 35 
received (as treated)  36 
Material and Methods 37 
This research adheres to the principles set forth in the Declaration of Helsinki 38 
(http://www.wma.net/en/30publications/10policies/b3/index.html). For the purpose of the 39 
present post-hoc analysis, patients from the ART (n=3102) were classified according to an as treated 40 
principle depending on number of SVG and arterial grafts actually received. Patients receiving a 41 
single arterial graft (SAG) plus saphenous vein graft (SVG) were included in the SAG group; patients 42 
receiving 2 or more arterial grafts with additional SVG were included in the multiple arterial graft 43 
(MAG) group; patients receiving arterial grafts only included in the total arterial graft (TAG) group. 44 
The primary endpoint was 10-year survival.  Inverse probability of treatment weighting (IPTW) was 45 
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used for comparison.  In the present analysis we included only those patients who received 3 or 46 
more grafts.  Patients with no information on whether supplemental conduits were radial artery or 47 
vein (n=25), those who received 1 graft only (n=20), those not receiving at least 1 internal thoracic 48 
artery (n=35) or those where multiple arterial grafting was achieved exclusively using sequential 49 
single internal thoracic artery graft (n=85) were excluded.  50 
Trial design 51 
The ART was approved by the institutional review board of all participating centers, and informed 52 
consent was obtained from each participant. The protocol for the ART has been published [11]. 53 
Briefly, the ART is a 2-arm, randomized multicenter trial conducted in 28 hospitals in 7 countries, 54 
with patients being randomized equally to SITA or BITA grafts. Eligible patients were those with 55 
multivessel coronary artery disease involving at least the left anterior descending artery and the 56 
circumflex artery undergoing CABG including urgent patients. Only emergency patients (refractory 57 
myocardial ischemia/cardiogenic shock) and those requiring single grafts or redo CABG were 58 
excluded.  59 
Follow-up  60 
Questionnaires were sent to study participants by mail every year after surgery. No clinic visits were 61 
planned apart from the routine clinical 6-week post-operative visit. Participants were sent stamped 62 
addressed envelopes to improve the return rates of postal questionnaires. Study coordinators 63 
contacted participants by telephone to alert them to the questionnaire’s arrival and to ask them 64 
about medications, adverse events and health services resource use. 65 
Study outcomes 66 
For the present analysis the primary outcome was 10-year mortality and the composite of death, 67 
myocardial infarction, stroke and/or repeat revascularization.  68 
Definitions 69 
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ART definitions were used for the present analysis. The burden of native coronary artery disease 70 
was assessed by reporting the following four characteristics for each graft performed: quality of the 71 
target (1 to 3, 1=good, 2 moderate, 3=poor), vessel diameter assessed by means of intraoperative 72 
probes and the need for endarterectomy.     73 
Death was classified into cardiovascular and non-cardiovascular causes, where possible, using 74 
autopsy reports and death certificates. Congestive heart failure, arrhythmia or myocardial 75 
infarction, pulmonary embolus and dissection were considered cardiovascular causes of death. 76 
Because pulmonary embolus and dissection are not directly related to the conduits used, in the 77 
present analysis we considered all-cause death only. MI was diagnosed when two of the following 78 
three criteria were present: 1. Unequivocal ECG changes; 2. Elevation of cardiac enzyme(s) above 79 
twice the upper limit of normal or diagnostic troponin rises; 3. Chest pain typical for acute MI which 80 
lasted more than 20 minutes.  Stroke was defined as new neurological deficit evidenced by clinical 81 
signs of paresis, paraplegia or new cognitive dysfunction including any mental status alteration 82 
lasting more than 24 hours and/or evidence on CT or MRI scan of recent brain infarct (less than 6 83 
months). Repeat revascularization was defined as coronary bypass surgery or percutaneous 84 
coronary intervention (PCI) performed after the initial trial procedure.  85 
Statistical analysis 86 
Continuous variables were reported as mean and standard deviation and categorical variables were 87 
reported as count and percentage. The rate of missing data was less than 1% for all variables 88 
included in the propensity score model.  The mean and the most frequent value were used to impute 89 
continuous and categorical variables, respectively. To compare the three groups, inverse probability 90 
of treatment weighting (IPTW) was used and the treatment effect on the treated (ATT) was 91 
estimated to draw inferences about the relative effectiveness of the three treatment groups. For 92 
this purpose, a generalized boosted model was implemented to estimate propensity scores (PS) 93 
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adjusting for pre-treatment covariates, age, female sex, diabetes, chronic obstructive pulmonary 94 
disease (COPD), asthma, creatinine, left ventricular ejection fraction (LVEF), peripheral vascular 95 
disease (PVD), pre-operative atrial fibrillation (AF), myocardial infarction (MI), right coronary artery 96 
(RCA) disease, off-pump status, race, NYHA functional class, hypertension, hyperlipaemia, 97 
cerebrovascular disease. The propensity score was assumed as the probability that an individual 98 
with pre-treatment characteristics X receives SAG (twang R package). We gave each treatment case 99 
a weight of 1 and each comparison case a weight wi = p(xi)/(1 − p(xi)). The absolute standardised 100 
mean difference (SMD) was used as a balance metric to summarize the difference between two 101 
univariate distributions of a single pre-treatment variable. A value ≥0.10 was considered as an 102 
indicator of imbalance. The treatment effect estimates on primary endpoints were obtained by 103 
using a doubly robust estimation which combines a form of outcome regression (multivariate 104 
proportional hazard model) with a model for the exposure (i.e., IPTW). SAG was used as reference 105 
in all comparisons. A combination of IPTW and covariate adjustment corrects for residual imbalance 106 
after weighting. Moreover, treatment effect estimators that utilize an outcomes regression model 107 
and propensity scores are “doubly robust” in the sense that if either the propensity score model is 108 
correct or the regression model is correct then the treatment effect estimator will be unbiased. 109 
Treatment effect was reported as hazard ratio (HR) and 95% confidence interval (95%CI). Sub-110 
distribution HR were calculated for non-fatal endpoints (MI, stroke, repeat revascularization). 111 
Doubly robust adjustment was also used for test for trend analysis to investigate whether the 112 
hypothesis of an incremental benefit from MAG over SAG and from TAG over SAG.  Surgeon ID was 113 
included as a stratifying variable to account for surgeon related clustering effect. Treatment effect 114 
was also estimated after restricting analysis to patients older than 70 years and with insulin-115 
dependent diabetes. For sensitivity analysis we pooled TAG and MAG strategies in a single group 116 
(MAG/TAG group) and compared with a SAG using multivariable Cox regression model.  For 117 
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completeness, unadjusted comparisons were estimated forcing the treatment variable only in the 118 
regression model. 119 
For each patient, we also calculated the TAG index according to the following formula: 120 
  121 
𝑇𝐴𝐺 𝑖𝑛𝑑𝑒𝑥 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐴𝑟𝑡𝑒𝑟𝑖𝑎𝑙 𝐺𝑟𝑎𝑓𝑡𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑇𝑜𝑡𝑎𝑙 𝐺𝑟𝑎𝑓𝑡𝑠
 122 
The TAG index is an intuitive index of the proportion of revascularization achieved with arterial 123 
grafts. TAG index =1 correspond to arterial grafts only (TAG) while TAG index =0 corresponds to 124 
revascularization with SVG only.  By forcing the TAG index (as a continuous and categorial variable 125 
as < ;  𝑡𝑜 ; >  ) into a multivariable Cox model stratified by number of total grafts, we tested 126 
the hypothesis of a significant relationship between the proportion of arterial revascularization and 127 
a reduction of 10 year-adverse events. The relationship between different values of TAG index and 128 
risk of adverse events was reported as hazard ratio (HR) and 95% confidence interval (95%CI) using 129 
the median value of TAG index as reference.  130 
All p-values <0.05 were considered as indicating statistical significance. As sensitivity analysis, 131 
treatment effect was tested in a multivariable Cox regression analysis stratified by number of grafts.  132 
All statistical analysis was performed using R Statistical Software (version 3.2.3; R Foundation for 133 
Statistical Computing, Vienna, Austria). 134 
Results 135 
The final population consisted of 1084, 1010 and 390 patients in the SAG, MAG and TAG group 136 
respectively.  Only 139 (5.6%) patients did not complete the 10-year follow up, 59 (5.4%) in the SAG, 137 
56 (5.5%) in the MAG and 24 (6.1) in the TAG group.  The mean follow-up in this group was 5.2 years.  138 
The graft configuration used in each group is summarised in Supplementary Table 1. The three 139 
groups presented some differences in baseline characteristics (Table 1, average SMD>0.10).  In 140 
particular, patients in the TAG group were 2 years younger on average and were less likely to have 141 
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a concomitant RCA disease, a worse NYHA functional class but more likely to have an LVEF <50%.  142 
Guideline directed medical therapy at 10 years is shown in Supplementary Table 4. PS weighting 143 
created 3 groups comparable for all baseline characteristics (Table 2, Figure 1, Supplementary Table 144 
2 and Supplementary Figure 2). The distinction between cardiovascular and non-cardiovascular 145 
cause of death is presented in Supplementary Table 5, and supplementary Table 6 shows the 146 
incidence of sternal wound infection requiring reconstruction. 147 
10 year-outcome analysis is reported in Table 3. In the PS-weighted sample, we observed a 148 
significant trend toward a reduction of 10-year mortality across the three groups (test for trend 149 
=0.02; Figure 2A) and TAG was associated with a significant risk reduction of all-cause death when 150 
compared to SAG (HR 0.68; 95% CI 0.48-0.96;P=0.03). The same trend was observed for the 151 
revascularization (P=0.04) and the composite of death/MI/stroke and repeat revascularization 152 
(P=0.01) with TAG being associated with a significant risk reduction of the composite of 153 
death/MI/stroke and repeat revascularization (0.71; 95%CI 0.53-0.94; P=0.02; Figure 2B) when 154 
compared to SAG. 155 
The results of analysis in patients older than 70 years old and insulin-dependent diabetic patients 156 
are depicted in supplementary Tables 7, 8. TAG was associated with a lower incidence of mortality, 157 
and both MAG and TAG with lower incidence of the composite of mortality, MI, stroke and/or 158 
revascularization in insulin-dependent diabetic patients. Multivariable Cox models (Supplementary 159 
Table 3) confirmed that when compared to SAG, TAG was associated with a significant risk reduction 160 
of 10-year mortality and that MAG and TAG were associated with a significant risk reduction of the 161 
composite of death, MI, stroke and repeat revascularization.  162 
When TAG and MAG strategies were pooled together in a single group (MAG/TAG group), they were 163 
superior to SAG in terms of 10-year mortality and incidence of MACCE (Supplementary Table 164 
9).  Supplementary Table 10 depicts the unadjusted treatment effect estimation. 165 
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Finally, we observed a significant linear relationship between the TAG index and the risk of 10-year 166 
mortality (HR 0.68; 95% CI 0.47-0.97; P=0.03 ) and composite outcome (HR 0.68; 95%CI 0.51-167 
0.90;P=0.007, Figure 3A and Figure 3B; Table 4). When the TAG index was used as categorial 168 
variable, when compared to cases with TAG index < ,  a larger proportion of arterial 169 
revascularization (TAG index between  and  or TAG index >  ) was associated with a 170 
significantly lower risk of 10-year mortality and composite of death/MI/stroke and repeat 171 
revascularization.  172 
Discussion 173 
The main finding of the present post-hoc analysis of the ART was that we observed an incremental 174 
benefit in moving from SAG to MAG and TAG in terms of reduction of 10-year mortality and the 175 
composite of death/MI/stroke and repeat revascularization. When compared to SAG, MAG group 176 
showed a numerically lower rate of 10-year mortality and the composite of death, MI, stroke and 177 
revascularization. In the TAG group, this difference became statistically significant.  178 
For each patient, we calculated the TAG index which is an intuitive index of the proportion of 179 
revascularization achieved with arterial grafts. We found that there was a liner relationship between 180 
the TAG index and the risk reduction in 10-year mortality and composite endpoint.  181 
Despite recent advances in secondary prevention following CABG, including statin therapy and 182 
dual antiplatelet therapy [12], long-term SVG patency rates still remain inferior to those of arterial 183 
grafts [2-3]. SVG failure can occur in up to 40% of patients and it is associated with a significantly 184 
increased risk of the composite of adverse events [13]. However, SVG is still widely used during 185 
CABG not only to supplement the SITA graft but also when additional arterial grafts are used [14]. 186 
The exclusive use of arterial grafts is perceived as technically more demanding [15] and remains 187 
largely underutilized [14]. This is partially due to the limited evidence supporting the superiority of 188 
TAG over other revascularization strategies using SVG.  A recent meta-analysis of four small 189 
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randomized controlled trials [16] with short term follow-up, plus 21 observational studies found 190 
that when compared to no-TAG, TAG was associated with reduced long-term all-cause mortality in 191 
observational studies matched/adjusted for confounders (incident rate ratio 0.85, 95% CI: 0.81–192 
0.89, p = 0.0001; I2 =0%) and unmatched/unadjusted (incident rate ratio 0.67, 95% CI: 0.59–0.76, 193 
p = 0.0001; I2 = 67%). Decreases in major cardiovascular outcomes and revascularization did not 194 
achieve statistical significance. Moreover, when compared to patients with two arterial grafts, TAG 195 
was still associated with reduced long-term all-cause mortality (incident rate ratio 0.85, 95% CI: 196 
0.73–0.99, p=0.04) with minimal heterogeneity (I2=5%). 197 
The ART trial was designed to compare 10-year survival after BITA vs SITA grafts. No significant 198 
differences were found at 10 years between the 2 groups according to the intention to treat 199 
analysis [10]. However, the relatively high rate of cross-over (14%) may have influenced these 200 
results and an exploratory analysis supported the hypothesis that patients receiving 2 or more 201 
arterial grafts was associated with a lower risk of mortality. However, a large proportion of 202 
patients receiving additional arterial grafts were also treated with SVG to complete surgical 203 
revascularization and what remains unclear it is whether the exclusive use of arterial grafts was 204 
associated with a further benefit.   205 
The present post-hoc analysis of the ART trial showed that both MAG with additional SVG and TAG 206 
were associated with a numerically lower incidence of adverse events (mortality and composite of 207 
mortality, MI, stroke and/or revascularization) but TAG was associated with a larger and statistically 208 
significant advantage. In particular, TAG was associated with a significant reduction of 10-year 209 
mortality and rate of repeat revascularization.  When analysis was restricted to high risk subgroups, 210 
TAG and MAG strategies were beneficial in  patients with insulin-dependent diabetes but not in 211 
patients older than 70 years. These results  are supported by a recent study from New York State 212 
[17] which reporting that MAG was beneficial only in patients younger than 70 years old but not in 213 
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diabetic patients. However this analysis did not discriminate between insulin-dependent and orally 214 
treated subjects.  215 
We also found an inverse association between the risk of 10-year adverse events and the proportion 216 
of revascularization achieved with arterial grafts (TAG index).  217 
Although the present comparison is observational in nature, propensity score weighed groups were 218 
comparable for all relevant characteristics. Moreover, it should be noted that patients enrolled in a 219 
trial are more homogeneous than those from observational cohorts.  220 
Despite this, however, the main limitation of the present analyses is that it remains a  non 221 
randomized comparison.  While propensity score modelling included all baseline variables, we 222 
cannot exclude a residual selection bias based on unmeasured or unmeasurable characteristics. 223 
Moreover, assessment of extension and severity of native coronary disease was based on 224 
qualitative surgeon assessment and not on the SYNTAX score.   225 
In the ART when patients were randomized between 2004-2007 the only formal exclusion criteria 226 
were patients requiring a single graft, redo patients or those with evidence of an evolving 227 
myocardial infarction. However the ART  population may now, by current standards, be 228 
considered low risk for CABG and their generalizability to a contemporary cohort of patients, who 229 
are more likely to be older and sicker, remains to be determined. 230 
Additionally, the impact of surgeon expertise in ART has been addressed in a previous paper using 231 
the BITA conversion of BITA to SITA rate as a proxy of surgical expertise [18]. This approach could 232 
not be replicated in the present study due to the lack of information regarding the use of radial 233 
artery. However, to account for the potential influence of individual surgeon experience, our 234 
modelling of outcomes was stratified according to the surgeon performing the operation and 235 
results showed a favourable effect of TAG on 10-year incidence of death and of both MAG and 236 
TAG on the composite of death, stroke, myocardial infarction and revascularization. 237 
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In conclusion, the present post-hoc ART analysis showed that in ART there was an increasing 238 
benefit on 10-year outcomes by increasing the extension of arterial revascularization. As a 239 
consequence, MAG and TAG were associated with lower incidence of adverse events but TAG was 240 
associated with the greatest benefit. These findings support the hypothesis that both MAG and 241 
TAG represent valuable strategies in order to improve clinical outcomes following CABG but TAG 242 
can potentially provide further benefit in an appropriately selected population. Further studies 243 
including the ongoing ROMA trial [19], are necessary to provide final evidence into the potential 244 
benefit of total arterial revascularization.  245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
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Figure legends 324 
Figure 1. The Love plot shows the changes in standardized mean difference before and after 325 
matching. It demonstrates that the balance of covariates was improved on all variables, which are 326 
below the threshold of 0.1 of absolute mean difference.  327 
Figure 2A. Kaplan-Meier curves showing cumulative 10-year mortality in the three groups after 328 
inverse probability of treatment weighting (IPTW). The confidence limit of each curve is shown as 329 
shaded area. SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft. 330 
Figure 2B. Kaplan-Meier curves show cumulative 10-year incidence of composite of death, MI, 331 
stroke and repeat revascularization in the three groups after inverse probability of treatment 332 
weighting (IPTW). The confidence limit of each curve is shown as shaded area. SAG single arterial 333 
graft, MAG multiple arterial graft, TAG total arterial graft.  334 
Figure 3A. Linear relationship between the TAG index and the risk of 10-year mortality. TAG index 335 
median (0.5) as reference.  336 
Figure 3B. Kaplan-Meier curve show cumulative 10-year mortality according to the TAG index. The 337 
confidence limit of each curve is shown as shaded area. 338 
Supplementary Figure 1. Standardized mean difference before and after inverse probability of 339 
treatment weighting for each comparison (1: single arterial graft (SAG), 2: multiple arterial graft 340 
(MAG); 3: total arterial graft (TAG)).  341 
 342 
 343 
 344 
 345 
  346 
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Table 1. Patients characteristics in the original sample 347 
Values are presented as mean (±standard deviation) or n (%). SAG, single arterial graft, MAG multiple arterial graft, TAG total 348 
arterial graft. SMD, standardized mean difference. NYHA, New York Heart Association, COPD Chronic Obstructive Pulmonary 349 
Disease, LVEF Left Ventricle Ejection Fraction, PVD Peripheral Vascular Disease, AF Atrial Fibrillation, MI myocardial infarction, RCA 350 
right coronary artery.  351 
 352 
  353 
 SAG MAG TAG P-value SMD 
n  1084 1010 390   
Age 64.20 (8.92) 63.42 (8.86) 62.03 (8.95) <0.001 0.162 
Non-Caucasian  93 ( 8.6) 91 ( 9.0) 24 ( 6.2) 0.213 0.072 
Female gender 145 (13.4) 118 (11.7) 57 (14.6) 0.276 0.058 
NYHA functional class 3-4 224 (20.7)         237 (23.5) 60 (15.4)    0.004 0.137 
Diabetes 253 (23.3) 237 (23.5) 106 (27.2) 0.275 0.059 
COPD 31 ( 2.9) 25 ( 2.5) 6 ( 1.5) 0.357 0.060 
Asthma 38 ( 3.5) 52 ( 5.1) 22 ( 5.6) 0.098 0.068 
Creatinine 98.00 (21.85) 96.74 (20.95) 95.07 (20.31) 0.056 0.093 
LVEF<50% 273 (25.2) 221 (21.9) 109 (27.9) 0.039 0.094 
PVD  73 ( 6.7) 72 ( 7.1) 21 ( 5.4) 0.501 0.048 
AF 18 ( 1.7) 13 ( 1.3) 4 ( 1.0) 0.602 0.037 
MI 481 (44.4) 398 (39.4) 161 (41.3) 0.068 0.067 
Cerebrovascular disease 31 ( 2.9)       35 ( 3.5)     5 ( 1.3)    0.089    0.096 
Hypertension 852 (78.6)      758 (75.0)     303 (77.7) 0.147 0.056 
Hyperlipidemia 1016 (93.7)    949 (94.0)     364 (93.3)    0.908 0.017 
RCA 876 (80.8) 871 (86.2) 264 (67.7) <0.001 0.301 
Off-pump 413 (38.1) 403 (39.9) 175 (44.9) 0.064 0.092 
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Table 2. Patients characteristics in the PS-weighted sample 354 
Values are presented as mean (±standard deviation) or n (%). SAG, single arterial graft, MAG multiple arterial graft, TAG total 355 
arterial graft. SMD, standardized mean difference. NYHA, New York Heart Association, COPD Chronic Obstructive Pulmonary 356 
Disease, LVEF Left Ventricle Ejection Fraction, PVD Peripheral Vascular Disease, AF Atrial Fibrillation, MI myocardial infarction, RCA 357 
right coronary artery. 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
 371 
 SAG MAG TAG P-value   SMD    
n  1084.00         941 843   
Age   64 (9)         64 (9) 64 (9) 0.953        0.011 
Non-Caucasian  93 ( 8.6) 74 ( 7.9) 42 ( 4.9) 0.054        0.098 
Female gender  145 (13.4)        110 (11.7) 121 (14.4) 0.407        0.054 
NYHA functional class 
3-4 
224 (20.7)    195 (20.8)    142 (16.9)    0.200        0.067 
Diabetes 253 (23.3)    215 (22.8)    201 (23.8)    0.916        0.015 
COPD  31 (2.9)         25 (2.7) 11 (1.3)    0.193        0.072 
Asthma  38 ( 3.5)        32 ( 3.4)     25 ( 3.0) 0.799        0.020 
Creatinine  98 (22)   98 (20)   97 (20)   0.835        0.022 
LVEF<50%  273 (25.2)    225 (23.9)    226 (26.8)    0.523        0.045 
PVD  73 (6.7)        66 ( 7.0) 56 ( 6.7)    0.965        0.008 
AF  18 ( 1.7)         12 ( 1.3) 6 ( 0.8)    0.311        0.055 
MI  481 (44.4)    403 (42.9)    366 (43.4)    0.840        0.020 
Cerebrovascular         
disease 
31 ( 2.9)       30 ( 3.2) 13 (1.5)    0.230        0.074 
Hypertension 852 (78.6)    729 (77.5)    662 (78.5)    0.857        0.018 
Hyperlipidemia 1016 (93.7)          889 (94.4)    785 (93.2)    0.652 0.035 
RCA 876 (80.8)         776 (82.5)    665 (78.8)    0.299 0.062 
Off-pump 413 (38.1)          349 (37.1)    330 (39.1)    0.757 0.028 
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Table 3. Treatment effect estimation  372 
  10-y cumulative 
incidence 
 HazardRatio         CI.95     p-value  
All-cause death (P-trend=0.02) 
           SAG 24.6%          Ref                            
                 MAG 21.1% 0.84 [0.69;1.03] 0.09 
                 TAG 18.4% 0.68 [0.48;0.96] 0.03 
MI (P-trend=0.43) 
           SAG 5.5%          Ref                            
                 MAG 4.8% 0.85 [0.55;1.32] 0.47 
                 TAG 5.2% 0.82 [0.45;1.47] 0.50 
Revascularization (P=0.04) 
           SAG 11.3%          Ref                            
                 MAG 11.3% 0.82  [0.61;1.12] 0.22 
                 TAG 10.1% 0.64 [0.41;1.00] 0.05 
STROKE (P-trend=0.65) 
           SAG 5.6%          Ref                            
                 MAG 4.4% 0.83 [0.53;1.30] 0.42 
                 TAG 5.7% 1.29 [0.57;2.92] 0.53 
Death/MI/STROKE/revascularization (P-trend=0.01) 
           SAG 37.0%          Ref                            
                 MAG 32.1% 0.82 [0.69;0.96] 0.02  
                 TAG 31.4% 0.71 [0.53;0.94] 0.02  
 SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft. MI, myocardial infarction.  373 
  374 
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Table 4. Multivariable Cox regression to test the association between the TAG index and outcomes 375 
of interest 376 
  10-year mortality  10-year MACE 
Variable  Units HR CI.95 p-value  HR CI.95 p-value 
TAG index ≤1/3 Ref    Ref   
                                     1/3-2/3 0.85   [0.70;1.04]     0.11   0.84  [0.72;0.99]  0.03 
                                     >2/3 0.73   [0.57;0.93]     0.01   0.75  [0.62;0.92]  0.004 
 Continuous  0.68   [0.47;0.97]     0.03   0.68 [0.51;0.90]    0.007 
Age   1.07   [1.06;1.08]     < 0.001   1.03   [1.02;1.04]     < 0.001  
Non-Caucasian   0.72   [0.46;1.11]     0.13   0.76   [0.56;1.04]     0.08266  
Female  0.96   [0.74;1.24]     0.73   1.17   [0.96;1.44]     0.11558  
NYHA functional class  1.11   [0.90;1.38]     0.33  1.15   [0.97;1.37]     0.10295  
DM  1.33   [1.10;1.61]     0.004   1.15   [0.98;1.35]     0.07996  
COPD   1.14   [0.72;1.80]     0.57   1.09   [0.73;1.62]     0.67814  
Asthma   1.32   [0.90;1.92]     0.15   1.64   [1.23;2.19]     < 0.001  
Creatinine   1.01   [1.00;1.01]     < 0.001   1.00   [1.00;1.01]     0.03723  
LVEF   1.76   [1.46;2.12]     < 0.001   1.28   [1.09;1.50]     0.00232  
PVD   1.35   [1.02;1.80]     0.04   1.39   [1.09;1.77]     0.00715  
AF  2.14   [1.35;3.39]     0.001   1.71   [1.10;2.66]     0.01710  
MI   1.09   [0.91;1.30]     0.35   1.08   [0.93;1.24]     0.31520  
CVD   1.49   [1.01;2.19]     0.04   1.35   [0.96;1.90]     0.08392  
Hypertension  1.22   [0.96;1.54]     0.10   1.16   [0.97;1.39]     0.11294  
Hyperlipidaemia  0.94   [0.66;1.34]     0.73   0.86   [0.65;1.13]     0.27583  
RCA   1.08   [0.85;1.35]     0.54  1.04   [0.87;1.25]     0.66037  
Off-pump   1.08   [0.90;1.30]     0.41  1.00   [0.86;1.17]     0.96181  
MACE major adverse cardiac events, NYHA New York Heart Association, DM diabetes mellitus, COPD Chronic Obstructive Pulmonary 377 
Disease, LVEF left ventricle ejection fraction, PVD peripheral vascular disease, AF atrial fibrillation, MI myocardial infarction, CVD 378 
cerebrovascular disease, RCA right coronary artery, EA endarterectomy. 379 
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Supplementary Table 1. Graft configuration  
SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft, SITA single internal thoracic artery, SVG saphenous vein graft, BITA bilateral internal thoracic artery, RA radial 
artery. 
 
Group SAG MAG TAG 
Total n 1084 1010 390 
Graft Conf SITA+SVG BITA+SVG SITA+RA+SVG BITA+RA+SVG BITA only SITA+RA BITA+RA 
n (%) 1084 (100.0) 775 (100.0) 189 (100.0) 46 (100.0) 62 (100.0) 101 (100.0) 227 (100.0) 
Sequential n(%)  195 (18.0) 134 (17.3) 44 (23.3) 6 (13.0) 62 (96.8) 77 (76.2) 69 (30.4) 
Supplementary Table 2. Standardised mean difference between individual group 1 
comparison before and after IPTW.  2 
    Unmatch
ed 
average 
Unmatched 
SAGvsMAG 
Unmatc
hed  
SAGvsM
AG 
Unmatch
ed 
 
MAGvsTA
G 
Weighted 
average 
Weighted 
SAGvsMA
G 
Weighted 
SAGvsTA
G 
Weighted 
MAGvsTA
G 
  Age    0.16    0.09   0.24   0.16   0.01    0.01   0.005   0.02  
  Female   0.06   0.05    0.04  0.09   0.05    0.05    0.03  0.08  
  DM   0.06  0.003   0.09  0.09    0.01    0.01    0.01   0.02 
  COPD   0.06    0.02   0.09   0.07   0.07     0.01     0.11   0.10 
  Asthma   0.07   0.08    0.10   0.02    0.02  0.004   0.03   0.03 
  Creatinine  0.09    0.06    0.14  0.08    0.02    0.02     0.03    0.01  
  LVEF   0.09    0.08    0.06     0.14    0.05     0.03    0.04  0.07  
  PVD   0.05   0.02   0.06  0.07   0.008    0.009   0.003    0.01  
  AF  0.04   0.03   0.06  0.02    0.06   0.03   0.08   0.05  
  MI   0.07    0.10   0.06   0.04   0.02     0.03    0.02  0.01  
  RCA   0.30     0.15   0.30    0.45    0.06    0.04     0.05  0.09  
  Off-pump   0.09    0.04   0.14   0.10   0.03   0.02    0.02   0.04  
  Non-caucasian   0.07    0.01   0.09     0.10    0.10    0.03    0.15    0.12  
NYHA functional 
class  
  0.14   0.07   0.14   0.21   0.07   0.0027   0.10  0.10 
  Hypertension   0.06   0.    0.02   0.06    0.02   0.03  0.003   0.02  
  
Hyperlipidaemia  
 0.02  0.01  0.02  0.03   0.03    0.03    0.02   0.05  
  CVD  0.10   0.03     0.11    0.14    0.07    0.02   0.09    0.11  
Table 1 SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft. IPTW inverse probability of treatment 3 
weighting. DM diabetes mellitus, COPD chronic obstructive pulmonary disease, LVEF left ventricle ejection fraction, PVD 4 
peripheral vascular disease, AF atrial fibrillation, MI myocardial infarction, VQ vessel quality, RCA right coronary artery, 5 
NYHA New York Heart Association, CVA cerebrovascular disease. 6 
  7 
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Supplementary Table 3. Multivariable Cox model stratified by number of grafts 1 
  10-year mortality  10-year MACE 
  Variable  Units HR CI.95 p-value  HR CI.95 p-value 
     group *† SAG Ref    Ref   
            MAG 0.86 [0.71;1.04] 0.12  0.83 [0.71;0.97] 0.01 
            TAG 0.77 [0.58;0.97] 0.04  0.78 [0.63;0.97] 0.02 
Age   1.07 [1.06;1.08] < 0.001  1.03 [1.02;1.04] < 0.001 
Non-caucasian   0.73 [0.47;1.13] 0.16  0.77 [0.57;1.05] 0.10 
Female  0.93 [0.72;1.20] 0.57  1.15 [0.94;1.41] 0.17 
NYHA functional class  1.10 [0.89;1.36] 0.40  1.15 [0.97;1.36] 0.11 
DM   1.33 [1.10;1.62] 0.003  1.15 [0.98;1.35] 0.08 
COPD   1.16 [0.74;1.84] 0.51  1.08 [0.73;1.61] 0.69 
Asthma   1.31 [0.90;1.92] 0.16  1.66 [1.25;2.22] < 0.001 
Creatinine   1.01 [1.00;1.01] < 0.001  1.00 [1.00;1.01] 0.034 
LVEF   1.76 [1.46;2.12] < 0.001  1.28 [1.09;1.50] 0.002 
PVD   1.38 [1.03;1.83] 0.03  1.40 [1.10;1.78] 0.006 
AF pre   2.20 [1.39;3.48] < 0.001  1.74 [1.12;2.71] 0.01 
MI   1.09 [0.91;1.31] 0.33  1.08 [0.93;1.25] 0.30 
CVD  1.52 [1.03;2.24] 0.03  1.37 [0.98;1.93] 0.07 
Hypertension  1.21 [0.96;1.53] 0.10  1.16 [0.96;1.38] 0.12 
Hyperlipidemia  0.96 [0.67;1.37] 0.80  0.87 [0.66;1.15] 0.32 
RCA   1.13 [0.90;1.43] 0.30  1.08 [0.89;1.30] 0.44 
Off-pump   1.09 [0.91;1.32] 0.35  1.01 [0.87;1.17] 0.90 
SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft. MACE major adverse cardiac events, NYHA 2 
New York Heart Association, DM diabetes mellitus, COPD Chronic Obstructive Pulmonary Disease, LVEF left ventricle 3 
ejection fraction, PVD peripheral vascular disease, AF atrial fibrillation, MI myocardial infarction, CVD cerebrovascular 4 
disease, RCA right coronary artery, EA endarterectomy. 5 
*P-value for test for trend=0.03 for mortality.  6 
†P-value for test for trend=0.006 for MACE 7 
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Supplementary Table 4. Compliance to goal directed medical therapy in the three groups.  1 
 SAG MAG TAG 
n 593 (54.7%) 625 (61.9%) 240 (61.5%) 
Aspirin 80.6% 81.3% 83.3% 
Statins 91.3% 91.0% 88.0% 
Angiotensin Converting Enzyme inhibitors 54.3% 56.7% 59.0% 
Beta-blockers 77.3% 72.5% 68.3% 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
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Supplementary Table 5. Comparison of cardiac vs non-cardia cause of death in the three 1 
groups.  2 
 SAG MAG TAG P value 
N (%) 1084 941 843  
Cardiovascular 
death 
91 ( 8.4)     74 ( 7.8) 55 ( 6.5)    
0.220 
Non cardiovascular 
death 
165 (15.2)   118 (12.5)    95 (11.3) 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
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 16 
 17 
 18 
 19 
 20 
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 22 
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Supplementary Table 6. Incidence of sternal wound infection requiring reconstruction in the 1 
groups.  2 
 SAG MAG TAG P value 
N (%) 1084 941 843  
Sternal wound 
infection 
4 (15.4)         8 (20.7) 6 (11.0) 0.60 
 3 
 4 
 5 
 6 
 7 
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Supplementary Table 7. Treatment effect estimation in patient older than 70 years old 1 
    10-y cumulative 
incidence 
Hazard Ratio CI.95 p-value 
All-cause death (P-trend=0.15) 
            SAG 41.7% Ref   
            MAG 37.8% 0.91 [0.66;1.25] 0.55 
 TAG 29.3% 0.67 [0.39;1.17] 0.16 
Death/MI/STROKE/revascularization (P-trend=0.09) 
            SAG 51.3% Ref   
 MAG 47% 0.95 [0.72;1.25] 0.70 
            TAG 42.3% 0.65 [0.40;1.07] 0.09 
SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft. MI, myocardial infarction. 2 
 3 
 4 
 5 
 6 
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Supplementary Table 8. Treatment effect estimation in insulin-dependent diabetic patients.  1 
    10-y cumulative 
incidence 
Hazard Ratio CI.95 p-value 
All-cause death (P-trend=0.02) 
            SAG 24.6% Ref   
            MAG 21.1% 0.84 [0.69;1.03] 0.10 
 TAG 18.4% 0.68 [0.48;0.96] 0.03 
Death/MI/STROKE/revascularization (P-trend=0.007) 
            SAG 37.0% Ref   
 MAG 32.1% 0.82 [0.69;0.96] 0.02 
            TAG 31.4% 0.71 [0.53;0.94] 0.02 
SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft. MI, myocardial infarction. 2 
 3 
 4 
 5 
 6 
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Supplementary Table 9. Treatment effect estimation of MAG/TAG group vs SAG according 1 
to multivariable model and without propensity score.  2 
  10-y cumulative 
incidence 
 HazardRatio         CI.95     p-value  
All-cause death  
           SAG 24.6%          Ref                            
                 
MAG/TAG 
19.5% 0.78 [0.65;0.92] 0.004 
MI  
           SAG 5.5%          Ref                            
                 
MAG/TAG 
4.9% 0.85 [0.59;1.22] 0.38 
Revascularization  
           SAG 11.3%          Ref                            
                 
MAG/TAG 
10.8% 0.91 [0.71;1.18] 0.49 
STROKE  
           SAG 5.6%          Ref                            
                 
MAG/TAG 
4.2% 0.73 [0.50;1.07] 0.10 
Death/MI/STROKE/revascularization  
           SAG 37.0%          Ref                            
                 
MAG/TAG 
30.8% 0.79 [0.68;0.90] <0.001 
SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft. MI, myocardial infarction 3 
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 5 
 6 
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Supplementary Table 10. Treatment effect estimation in the overall population without 1 
adjustment.  2 
  10-y cumulative 
incidence 
 HazardRatio         CI.95     p-value  
All-cause death (P-trend=0.003) 
           SAG 24.6%          Ref                            
                 MAG 20.2% 0.80 [0.67;0.97] 0.02 
                 TAG 17.9% 0.71 [0.54;0.93] 0.01 
MI (P-trend=0.33) 
           SAG 5.5%          Ref                            
                 MAG 5.0% 0.88 [0.60;1.30] 0.53 
                 TAG 4.6% 0.77 [0.44;1.35] 0.37 
Revascularization (P=0.35) 
           SAG 11.3%          Ref                            
                 MAG 11.1% 0.95 [0.72;1.24] 0.70 
                 TAG 9.9% 0.83 [0.56;1.21] 0.33 
STROKE (P-trend=0.09) 
           SAG 5.6%          Ref                            
                 MAG 4.3% 0.76 [0.51;1.15] 0.20 
                 TAG 3.7% 0.64 [0.35;1.18] 0.15 
Death/MI/STROKE/revascularization (P-trend=0.001) 
           SAG 37.0%          Ref                            
                 MAG 31.1% 0.80 [0.68;0.92] 0.003 
                 TAG 30.2% 0.76 [0.62;0.94] 0.01 
SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft. MI, myocardial infarction. 3 
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Figure 1. The Love plot shows the changes in standardized mean difference before and after 1 
matching. It demonstrates that the balance of covariates was improved on all variables, 2 
which are below the threshold of 0.1 of absolute mean difference.  3 
 4 
  5 
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Figure 2A. Kaplan-Meier curves showing cumulative 10-year mortality in the three groups 1 
after inverse probability of treatment weighting (IPTW). The confidence limit of each curve 2 
is shown as shaded area. SAG single arterial graft, MAG multiple arterial graft, TAG total 3 
arterial graft. 4 
 5 
  6 
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Figure 2B. Kaplan-Meier curves show cumulative 10-year incidence of composite of death, 1 
MI, stroke and repeat revascularization in the three groups after inverse probability of 2 
treatment weighting (IPTW). The confidence limit of each curve is shown as shaded area. 3 
SAG single arterial graft, MAG multiple arterial graft, TAG total arterial graft.  4 
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Figure 3A. Linear relationship between the TAG index and the risk of 10-year mortality. TAG 1 
index median (0.5) as reference.  2 
 3 
  4 
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Figure 3B. Kaplan-Meier curve show cumulative 10-year mortality according to the TAG 1 
index. The confidence limit of each curve is shown as shaded area. 2 
 3 
  4 
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Supplementary Figure 1. Standardized mean difference before and after inverse probability 1 
of treatment weighting for each comparison (1: single arterial graft (SAG), 2: multiple 2 
arterial graft (MAG); 3: total arterial graft (TAG)).  3 
 4 
 5 
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